Lutetium-177 Dotatate

The radiolabeled peptide is freely filtered and then reabsorbed in the proximal tubule via the megalin/cubilin scavenger-receptor system, where retained radioactivity delivers chronic radiation to the tubulointerstitium. The result is classic delayed radiation nephropathy — proximal tubular atrophy, interstitial fibrosis, and a thrombotic-microangiopathy-like glomerular/vascular injury — rather than an acute tubular insult. Co-infused cationic amino acids (lysine, arginine) competitively block megalin-mediated tubular reabsorption of the peptide, cutting renal radiation dose.

Usually subclinical and slowly progressive: a gradual creatinine rise and eGFR decline over months to years, sometimes with low-grade proteinuria. Acute toxicity is unusual; the lysine/arginine load itself can cause transient nausea and hyperkalemia during infusion.

Prevention is paramount because established radiation nephropathy is largely irreversible. Manage like other CKD: blood-pressure and proteinuria control (ACE inhibitor/ARB), avoid further nephrotoxins, and monitor GFR long-term. Hold or reduce subsequent cycles for significant renal or hematologic toxicity. Treat amino-acid-induced hyperkalemia supportively.Lesion-level management framework

Standard course is 7.4 GBq IV every 8 weeks for 4 cycles. There is no simple CrCl-based dose table; instead activity is governed by the renal radiation-tolerance threshold (classically ~23 Gy absorbed dose; a renal BED cap of ~37-40 Gy is used in dosimetry-guided practice). Baseline CrCl <30 mL/min or rapidly declining renal function is a contraindication/caution; reduce or omit cycles for grade >=2-3 renal toxicity.

Dialysis does not treat the toxicity itself — established radiation nephropathy is structural, not a removable circulating drug. But treating a hemodialysis-dependent (ESKD) patient is feasible and reported, not off-limits: because the radiopeptide is predominantly renally excreted, an anuric patient cannot excrete it, so reported protocols schedule hemodialysis after initial tumor uptake to strip circulating Lu-177 and limit whole-body/marrow dose. Removal is real but partial, and how much comes off differs sharply between reports: a two-cycle case that cut administered activity 33% then 45% and began postdilution hemodiafiltration 6 h and 5 h after dosing saw whole-body activity fall 40% and 47%, reproducing normal-clearance retention curves, while a separate dotatate patient lost 4.9% of total-body radioactivity per session averaged across his dialysis course. Activity already taken up by tumor, kidney, marrow and salivary tissue is beyond the membrane's reach at any timing. Amino-acid renoprotection is pointless in an anuric patient; the concern shifts to marrow dose and radioactive-dialysate handling, which can stay above release limits for weeks of later sessions. A 2024 ESKD treatment algorithm and case reports (including a completed 4-cycle course with sustained remission) describe safe delivery under hemodialysis.

Distinguish delayed radiation nephropathy (slow GFR decline, bland-to-mild proteinuria, TMA-like changes) from tumor-related obstruction, octreotide effects, contrast nephropathy and concomitant nephrotoxins. The slow, late trajectory and dosimetric history point to radiation injury.